Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varespladib Methyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A known ✓ | P14555 | 18/20 | 0.83 |
| ▸ | PLA2G10 known ✓ | O15496 | 7/20 | 0.83 |
| ▸ | PLA2G5 known ✓ | P39877 | 5/20 | 0.83 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.83 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 0.83 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 0.83 |
| ▸ | PLA2G2D | Q9UNK4 | 4/20 | 0.83 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.83 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.83 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.83 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.83 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varespladib Methyl SCHEMBL25678 | 1.00 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL818717 | 0.92 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710708 | 0.91 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6812616 | 0.91 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib SCHEMBL29358982 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib SCHEMBL26726 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5153686 | 0.91 | PLA2G2A (0.78) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL13632211 | 0.90 | PLA2G10 (0.84) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710700 | 0.89 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL14620967 | 0.89 | PLA2G2A (0.66) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619025-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107800-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240052352-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-02-15 | — | — | US | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| WO-2022178407-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-122094714-A | Cyclic peptide therapeutic methods | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4702027-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINE C-NUCLEOSIDE COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220127676-A1 | METHODS AND COMPOSITIONS FOR PROGNOSTIC AND/OR DIAGNOSTIC SUBTYPING OF PANCREATIC CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | IRAK4, IRAK1, IRAK2 | PLA2G2A 3027/4885PLA2G10 2629/4885PLA2G5 2391/4885 |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | PLA2G2A 4720/4885PLA2G10 4246/4885PLA2G5 4444/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PLA2G2A 1635/4885PLA2G10 2846/4885PLA2G5 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.